AGE-RELATED MACULAR DEGENERATION CURRENT INVESTIGATIONS AND TREATMENTS

agerelatedmaculardeg774enerationkapak

LASER PHOTOCOAGULATION AND PHOTODYNAMIC THERAPY

Erdem Dursun

Kırıkkale University, Faculty of Medicine, Department of Ophthalmology, Kırıkkale, Türkiye

Dursun E. Laser Photocoagulation and Photodynamic Therapy. In: Çıtırık M, Şekeryapan Gediz B, editors. Age-Related Macular Degeneration: Current Investigations and Treatments. 1st ed. Ankara: Türkiye Klinikleri; 2025. p.189-193.

ABSTRACT

Age-related macular degeneration (AMD) is a retinal disease that primarily affects older adults and often leads to vision loss in advanced stages. AMD involves damage to the macula, the central part of the retina responsible for sharp, central vision. The most common cause of vision loss is the development of choroidal neovascularisation (CNV), which is typical of wet AMD (wAMD). Laser treatments were used as the first treatment options for a long time in the 1990s with their effects on newly formed vascular structures in wAMD. With the discovery of Anti-Vascular Endothelial Growth Factor (Anti-VEGF), laser treatment modalities started to lose their former importance in wAMD treatments.

In Asian populations, vision loss due to wAMD is more commonly associated with polypoidal choroidal vasculopathy (PCV) than CNV. Current clinical trials of intravitreal anti-VEGF therapy and photodynamic therapy will provide clearer perspectives on the evidence-based management of PCV and may lead to changes in current treatment strategies for wAMD. In this chapter, the indications, benefits and limitations of these two therapeutic interventions in the treatment of wAMD will be discussed.

Keywords: Macular degeneration, Age related; Laser coagulation; Photochemotherapy

Referanslar

  1. Deng Y, Qiao L, Du M, Qu C, Wan L, Li J, Huang L. Age-related macular degeneration: Epidemiology, genetics, pathophysiology, diagnosis, and targeted therapy. Genes Dis. 2021;9(1):62-79. [Crossref]  [PubMed]  [PMC]
  2. Guymer RH, Campbell TG. Age-related macular degeneration. Lancet. 2023;401(10386):1459-1472. [Crossref]  [PubMed]
  3. Scott AW, Bressler NM, Ffolkes S, Wittenborn JS, Jorkasky J. Public Attitudes About Eye and Vision Health. JAMA Ophthalmol. 2016;134(10):1111-1118. [Crossref]  [PubMed]
  4. Taylor DJ, Hobby AE, Binns AM, Crabb DP. How does age-related macular degeneration affect real-world visual ability and quality of life? A systematic review. BMJ Open. 2016;6(12):e011504. [Crossref]  [PubMed]  [PMC]
  5. Thomas CJ, Mirza RG, Gill MK. Age-Related MacularDegeneration. Med Clin North Am. 2021;105(3):473-491. [Crossref]  [PubMed]
  6. Flaxel CJ, Adelman RA, Bailey ST, Fawzi A, Lim JI, Vemulakonda GA, Ying GS. Age-Related Macular Degeneration Preferred Practice Pattern®. Ophthalmology. 2020;127(1):1-65.doi:10.1016/j.ophtha.2020.06.048. [Crossref]
  7. Lim LS, Mitchell P, Seddon JM, Holz FG, Wong TY. Age-related macular degeneration. Lancet. 2012 5;379(9827):1728-38. [Crossref]  [PubMed]
  8. Rishi P, Mahavir S. Current Role of Photodynamic Therapy in Ophthalmic Practice. Sci. J. Med. Vis. Res. Foun.2015;33:97-99. [Link]
  9. Scott LJ, Goa KL. Verteporfin. Drugs Aging. 2000;16:139-146. [Crossref]  [PubMed]
  10. Newman DK. Photodynamic Therapy: Current Role in the Treatment of Chorioretinal Conditions. Eye. 2016;30:202-210. [Crossref]  [PubMed]  [PMC]
  11. Persistent and recurrent neovascularization after krypton laser photocoagulation for neovascular lesions of age-related macular degeneration. Macular Photocoagulation Study Group. Arch Ophthalmol. 1990;108(6):825-31. [Crossref]  [PubMed]
  12. Miller JW, Schmidt-Erfurth U, Sickenberg M, et al.: Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of a single treatment in a phase 1 and 2 study. Arch Ophthalmol 1999;117:1161-1173. [Crossref]  [PubMed]
  13. Bressler NM; Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: twoyear results of 2 randomized clinical trials-tap report 2. Arch Ophthalmol. 2001;119(2):198-207. [PubMed]
  14. Ruiz-Oliva F, Cortés J. Verteporfin in Photodynamic Therapy (VIP) Study group. Ophthalmology. 2002;109(6):1043; author reply 1043-4. [Crossref]  [PubMed]
  15. Tano Y; Ophthalmic PDT Study Group. Guidelines for PDT in Japan. Ophthalmology. 2008;115(3):585-585. [Crossref]  [PubMed]
  16. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY; MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419-31. [Crossref]  [PubMed]
  17. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS,Kim RY, Sy JP, Schneider S; ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1432-44. [Crossref]  [PubMed]
  18. Larsen M, Schmidt-Erfurth U, Lanzetta P, Wolf S, Simader C, Tokaji E, Pilz S, Weisberger A; MONT BLANC Study Group. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelvemonth MONT BLANC study results. Ophthalmology. 2012;119(5):992-1000. [Crossref]  [PubMed]
  19. Kaiser PK, Boyer DS, Cruess AF, Slakter JS, Pilz S, Weisberger A; DENALI Study Group. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month results of the DENALI study. Ophthalmology. 2012;119(5):1001-10. [Crossref]  [PubMed]
  20. Guymer RH, Campbell TG. Age-related macular degeneration. Lancet. 2023;401(10386):1459-1472. [Crossref]  [PubMed]
  21. Wong CW, Yanagi Y, Lee WK, Ogura Y, Yeo I, Wong TY, Cheung CMG. Age-related macular degeneration and polypoidal choroidal vasculopathy in Asians. Prog Retin Eye Res.2016;53:107-139. [Crossref]  [PubMed]
  22. Koh A, Lee WK, Chen LJ, Chen SJ, Hashad Y, Kim H, Lai TY, Pilz S, Ruamviboonsuk P, Tokaji E, Weisberger A, Lim TH. EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy. Retina.2012;32(8):1453-64. [Crossref]  [PubMed]
  23. Teo KYC, Park KH, Ngah NF, Chen SJ, Ruamviboonsuk P, Mori R, Kondo N, Lee WK, Rajagopalan R, Obata R, Wong IYH, Chee C, Terasaki H, Sekiryu T, Chen SC, Yanagi Y, Honda S, Lai TYY, Cheung CMG. Six-Year Outcomes in Subjects with Polypoidal Choroidal Vasculopathy in the EVEREST II Study. Ophthalmol Ther. 2024;13(4):935-954. [Crossref]  [PubMed]  [PMC]
  24. Zhao XY, Zhang WF, Meng LH, Wang DY, Chen YX. The polyp regression rate and treatment prognosis of different interventions for polypoidal choroidal vasculopathy: a systematic review and meta-analysis. Graefes Arch Clin Exp Ophthalmol. 2021;259(4):855-872. [Crossref]  [PubMed]